NCT00202956 is a Phase 2 clinical trial of Bugusan in Osteoporosis, sponsored by Taichung Veterans General Hospital.

Who is sponsoring NCT00202956?

NCT00202956 is sponsored by Taichung Veterans General Hospital.

What drugs are being tested in NCT00202956?

Interventions in NCT00202956: Bugusan.

What condition does NCT00202956 study?

NCT00202956 studies Osteoporosis.

Is NCT00202956 still recruiting?

NCT00202956 is currently status unknown. Last updated 12 September 2005.

Last reviewed 2005-09-12 · How we verify

NCT00202956

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects on Biomarkers and Safety of Bugusan (BGS) in Postmenopausal Patients With Osteoporosis.

Status unknown Phase 2 Last updated 12 September 2005

What this trial tests

Phase 2 trial testing Bugusan in Osteoporosis. Status unknown.

Timeline

1 June 2004

1 May 2005

Quick facts

Lead sponsor	Taichung Veterans General Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 June 2004
Estimated completion	1 May 2005
Sites	1 location across Taiwan

Drugs / interventions tested

Bugusan — full drug profile →

Conditions studied

Osteoporosis — all drugs for Osteoporosis →

Sponsor

Taichung Veterans General Hospital

Who can join

Adults 45 to 75, female only, with Osteoporosis.

Sponsor's own description

The objective is to evaluate the effects on biomarkers and safety of BGS in postmenopausal patients with osteoporosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

NCT07027306 — The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fract · recruiting
NCT07367776 — Patient Education in Osteoporosis (RCT-PATOS) · NA · recruiting
NCT06731608 — OsteoPorotic fracTure preventION System (OPTIONS) Research Study · NA · recruiting
NCT07281586 — Step-down Therapy After Long-term Osteoporosis Treatment · Phase 4 · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting

Other Taichung Veterans General Hospital trials

Trials by the same sponsor.

NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00202956 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
Last refreshed: 12 September 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00202956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing